Rua Myltho Anselmo da Silva, 870 - Mercês, Curitiba - PR, CEP 80510-130

Curitiba 80510-130

1 studies enrolling now · 1 studies all time

What they study most

Triple Negative Breast Cancer

Studies at this site

• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now